UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/664,213	09/16/2003	Hassan Mostafavi	005513P021	3361
Daniel E. Ovan	7590 08/22/200 ezian	EXAMINER		
BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP			MANTIS MERCADER, ELENI M	
Seventh Floor 12400 Wilshire	Boulevard	^	ART UNIT	PAPER NUMBER
Los Angeles, C	A 90025-1026		3768	•
			MAIL DATE .	DELIVERY MODE
			08/22/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Se
3	Application No.	Applicant(s)
	10/664,213	MOSTAFAVI ET AL.
Office Action Summary	Examiner	Art Unit
	Eleni Mantis Mercader	3737
The MAILING DATE of this communication ap Period for Reply	ppears on the cover sheet with	the correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING I Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  If NO period for reply is specified above, the maximum statutory period.  Failure to reply within the set or extended period for reply will, by stature Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICAL .136(a). In no event, however, may a report will apply and will expire SIX (6) MONTHE te, cause the application to become ABA	ATION.  ly be timely filed  IS from the mailing date of this communication.  NDONED (35 U.S.C. § 133).
Status		
<ul> <li>1) Responsive to communication(s) filed on 22 / 22</li> <li>2a) This action is FINAL. 2b) This action for allowed closed in accordance with the practice under</li> </ul>	is action is non-final. ance except for formal matte	•
Disposition of Claims		
4) ☐ Claim(s) 1-55 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-55 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/	awn from consideration.	
Application Papers		
9) The specification is objected to by the Examination The drawing(s) filed on is/are: a) ac Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction.  The oath or declaration is objected to by the Examination.	ccepted or b) objected to by e drawing(s) be held in abeyanc ction is required if the drawing(s	e. See 37 CFR 1.85(a). is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of:  1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	nts have been received. nts have been received in Apporting to a point of the comments have been read (PCT Rule 17.2(a)).	olication No eceived in this National Stage
Attachment(s)  1)   Notice of References Cited (PTO-892)	A) 🔲 Intonious Su	mman/PTO-413\
2) D Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/	mmary (PTO-413) Mail Date
<ol> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date</li> </ol>	5) Notice of Info 6) Other: Other	ormal Patent Application (PTO-152)  Further Dictionary com

Art Unit: 3768

### **DETAILED ACTION**

# Response to Arguments

1. Applicant's arguments filed on 8/22/2005 have been fully considered but they are not persuasive. According to the medical dictionary definition of Dictionary.com "implant" includes "To insert or embed (an object or a device) surgically: implant a drug capsule; implant a pacemaker". Therefore based on the broadest reasonable interpretation the fiducials of the Holupka et al.'007 are inserted and therefore implanted into the patient. With respect to the external imaging sources, please note that the ultrasound imager 23 as depicted in Figure 1 is external to the patient. Finally, the use of alternative matching techniques of images in order to be able to appropriately combine images from different modalities are well known functional equivalents producing the same end effect of image comparison. Therefore, all the rejections are maintained and made Final.

### **Double Patenting**

2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.



Art Unit: 3768

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 1, 2, 4 and 6 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 25 31, 33, 35 and 37 of copending Application No. 10/664,308. Although the conflicting claims are not identical, they are not patentably distinct from each other because Claims 1, 2, 4 and 6 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 25, 31, 33, 35, and 37 of copending Application No. 10/664,308. Although the conflicting claims are not identical, they are not patently distinct from each other because they represent alternate variations and groupings. The current claims are broader in scope in that they do not claim the sensor. Therefore, according to the rationale in re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993), in essence, once a patent was received for a species or a more specific embodiment, the applicant is not entitled to a patent for the generic or broader invention without maintaining common ownership and ensuring that the term of the latter issued patent will expire at the end of the original term of the earlier issued patent. This is because the more specific "anticipates" the broader.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

## Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person

Art Unit: 3768

having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

5. Claims 1-55 are rejected under 35 U.S.C. 103(a) as being unpatentable over Holupka et al. '007.

Holupka et al.'007 teach Holupka et al.'007 teach all the features of the current invention including the use of a plurality of markers/fiducials identifiable by two imaging modalities, ultrasound and CT for the purpose of a computer combining the images and providing an accurate image for delivering radiation therapy (see abstract and see col. 3, line 60-col. 6, line 37). Holupka et al.'007 teach that the radiation therapy and ultrasound isocenters are correlated (see col. 6, lines 50-67).

Holupka et al.'007 do not expressly state that the isocenter of the CT is correlated with the radiation therapy isocenter.

However, it would have been obvious to one skilled in the art that all the isocenters are correlated in order to create a common frame of reference and be able to fuse the images in guiding the therapy because otherwise there would be no common frame of reference.

The use of pixel analysis to identify the markers is well within the knowledge of skilled artisans as a well known image analysis technique to identify the area of interest.

According to the medical dictionary definition of Dictionary.com "implant" includes "To insert or embed (an object or a device) surgically: implant a drug capsule; implant a pacemaker". Therefore based on the broadest reasonable interpretation the fiducials of the Holupka et al.'007 are inserted and therefore implanted into the patient. With respect to the external imaging sources, please note that the ultrasound imager 23 as depicted in Figure 1 is external to the patient. Finally, the use of alternative matching techniques of images in order to be able to

Art Unit: 3768

1 ... · Q.

prication Control (value). 10/00/1,21

appropriately combine images from different modalities are well known functional equivalents producing the same end effect of image comparison.

#### Conclusion

6. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eleni Mantis Mercader whose telephone number is (571) 272-4740. The examiner can normally be reached on Mon. - Fri., 8:00 a.m.-6:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on (571) 272-4956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Page 6

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Elenlen Sur

Eleni Mantis Mercader Primary Examiner Art Unit 3737